Kawasaki disease
Kawasaki disease, also known as mucocutaneous lymph node syndrome (MCLS), is an acute febrile rash disease in children with systemic vasculitis as the main lesion. It was first reported by Japanese doctor Tomisaku Kawasaki in 1967. Since this disease can cause serious cardiovascular lesions, it has attracted people's attention. The incidence has increased in recent years. In 1990, among the inpatients with rheumatic diseases in Beijing Children's Hospital, there were 67 cases of Kawasaki disease and 27 cases of rheumatic fever; in the same data from 11 hospitals in other provinces and cities, Kawasaki disease was twice that of rheumatism. Obviously, Kawasaki disease has replaced rheumatic fever as one of the main causes of acquired heart disease in children in my country. Kawasaki disease is currently considered to be an immune-mediated vasculitis.
-
Site of disease:
Skin lymphatic heart -
Infectious :
Not contagious -
Frequent population:
Infants and young children -
Related symptoms:
Fever rash conjunctival congestion cervical lymphadenopathy persistent fever -
Concurrent disease:
Related Drugs
Intravenous human immunoglobulin (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura, Kawasaki disease.
Manufacturer:
Sinopharm Shanghai Plasma-derived Biotherapies Co., Ltd.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases such as idiopathic thrombocytopenic purpura, Kawasaki disease.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura and Kawasaki disease.
Manufacturer:
Shenzhen Weiguang Biological Products Co., Ltd.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura and Kawasaki disease.
Manufacturer:
Shenzhen Weiguang Biological Products Co., Ltd.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura and Kawasaki disease.
Lyophilized human immunoglobulin for intravenous injection (pH4)
Indication: 1. Primary immunoglobulin deficiency, such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency, immunoglobulin G subtype deficiency, etc. 2. Secondary immunoglobulin deficiency, such as severe infection, neonatal sepsis, etc. 3. Autoimmune diseases, such as idiopathic thrombocytopenic purpura, Kawasaki disease.
Manufacturer:
China Resources Boya Bio-pharmaceutical Group Co., Ltd.